Results 71 to 80 of about 12,617 (217)

Síndrome Hemolítico Urémico Atípico en Cuidados Intensivos: Caso Clínico de un Adulto [PDF]

, 2016
info:eu-repo/semantics ...
Agudo, I, Azevedo, L, Bento, L, Cavaco, R, Germano, N, Souto-Moura, T   +5 more
core   +1 more source

The Complement System in Post‐Transplant Kidney Injury

Organ Medicine, EarlyView.
Mengsi Hu
wiley   +1 more source

Nicotinamide Attenuates Complement and Coagulation Pathways and Resultant Renal Fibrosis

The FASEB Journal, Volume 39, Issue 23, 15 December 2025.
The coagulation and complement cascades were elevated in the pathogenesis of chronic kidney disease (CKD) and may contribute to both kidney injury and cardiovascular risk. These excessive signals and the associated innate immune responses were suppressed by the NAD+ precursor nicotinamide (NAM).
Saori Kin, Yuji Oe, Taku Obara, Emiko Sato, Nobuyuki Takahashi, Mariko Miyazaki, Tetsuhiro Tanaka   +6 more
wiley   +1 more source

Analysis of linear antibody epitopes on factor H and CFHR1 using sera of patients with autoimmune atypical hemolytic uremic syndrome [PDF]

, 2017
Introduction: In autoimmune atypical hemolytic uremic syndrome (aHUS), the complement regulator factor H (FH) is blocked by FH autoantibodies, while 90% of the patients carry a homozygous deletion of its homolog complement FH-related protein 1 (CFHR1 ...
Csuka, Dorottya, Józsi, Mihály, Kelen, Kata, Prohászka, Zoltán, Reusz, György, Szabó, Attila, Szilágyi, Ágnes, Trojnár, Eszter, Uray, Katalin   +8 more
core   +5 more sources

An Atypical Cause Of Atypical Hemolytic Uremic Syndrome

Marshall Journal of Medicine, 2016
Atypical hemolytic syndrome is an extremely rare, life threatening, progressive disease. Approximately one to two cases per million are seen annually in the US (3,4).
Abhinav Sharma, Carolina de Elia, Eric Arguelles , Christine L. Gilkerson   +3 more
doaj   +1 more source

Shiga toxin/verocytotoxin-producing Escherichia coli infections: practical clinical perspectives [PDF]

, 2014
Escherichia coli strains that produce Shiga toxins/verotoxins are rare, but important, causes of human disease. They are responsible for a spectrum of illnesses that range from the asymptomatic to the life-threatening hemolytic-uremic ...
Davis, T. K, Tarr, Phillip I, Van De Kar, Nicole C.A. J   +2 more
core   +2 more sources

The genetics of atypical hemolytic uremic syndrome [PDF]

Medizinische Genetik, 2018
Abstract Atypical hemolytic uremic syndrome (aHUS) is a disorder characterized by thrombocytopenia and microangiopathic hemolytic anemia due to endothelial injury. aHUS is felt to be caused by defective complement regulation due to underlying genetic mutations in complement regulators or activators, most often of the alternative pathway.
Feitz, W.JC., van de Kar, N.CA.J., Orth-Höller, D., van den Heuvel, L.PJ.W., Licht, C.   +4 more
openaire   +3 more sources

Pseudotumor Cerebri and Hemolytic Uremic Syndrome, A Rare Association

Clinical Case Reports, Volume 13, Issue 12, December 2025.
ABSTRACT Hemolytic uremic syndrome can present with central nervous system involvement. Idiopathic intracranial hypertension (IIH) is among the possible neurological manifestations of HUS, and clinicians should remain vigilant for extrarenal complications while treating patients with HUS.
Aasim Ali, Armaghana Abdullah, Mukesh Kumar Sharma, Anousha Tanveer, Muhammad Abdullah Mushtaq, Muhammad Mujtaba, Summaya Mushtaq   +6 more
wiley   +1 more source

Multiple Myeloma as the Underlying Cause of Thrombotic Microangiopathy Leading to Acute Kidney Injury: Revisiting a Very Rare Entity

Journal of Investigative Medicine High Impact Case Reports, 2017
Thrombotic microangiopathy (TMA) describes a pathological process of microvascular thrombosis, consumptive thrombocytopenia, and microangiopathic hemolytic anemia, leading to end-organ ischemia and infarction, affecting particularly the kidney and brain.
Savneek Chugh MD, Asim Kichloo MD, Firas Jafri MD, Liga Yusvirazi MD, Robert Lerner MD   +4 more
doaj   +1 more source

Soluble C5b‐9 (sC5b‐9) in Pediatrics—A Clinical Assessment

Journal of Clinical Laboratory Analysis, Volume 39, Issue 23, December 2025.
The sc5b9 assay is a simple laboratory‐developed test that can be used in specific patients to monitor the course of disease, severity, or response to therapy. Future studies using this assay, which show excellent adaptability to a clinical laboratory, will reveal the multiple uses of testing for complement activation.
Ridwan B. Ibrahim, Radwa Almamoun, Sarah E. Sartain, Sridevi Devaraj   +3 more
wiley   +1 more source